Dr. Ratna S. Danda, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 231
Licensed in Texas since 2005, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
TX license M2584 (first issued 2005; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Charlton Medical Center Dallas, TX
Medical groups
- Dallas Renal Group, P.a. (53 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 231
- Services billed
- 1,668
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 263 | 96 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 165 | 25 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 164 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 138 | 70 |
| Established patient office or other outpatient visit, 30-39 minutes | 138 | 85 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 117 | 32 |
| Established patient office or other outpatient visit, 20-29 minutes | 91 | 68 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 72 | 24 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 54 | 53 |
| Established patient office or other outpatient visit, 40-54 minutes | 41 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Losartan Potassium Other prescribers in Desoto, TX | 163 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Desoto, TX | 129 |
| Amlodipine Besylate Other prescribers in Desoto, TX | 107 |
| Furosemide Other prescribers in Desoto, TX | 85 |
| Hydralazine Hcl Other prescribers in Desoto, TX | 80 |
| Nifedipine Er (nifedipine) Other prescribers in Desoto, TX | 76 |
| Carvedilol Other prescribers in Desoto, TX | 70 |
| Jardiance (empagliflozin) Other prescribers in Desoto, TX | 50 |
| Prosol (parenteral amino acid 20% no.1) | 37 |
| Vitamin D2 (ergocalciferol (vitamin d2)) Other prescribers in Desoto, TX | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 55 payments worth $1,479 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $294 |
|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $273 |
| Amgen Inc. | $221 |
| Mallinckrodt Hospital Products Inc. | $93.01 |
| Opko Pharmaceuticals, LLC | $89.35 |
| Otsuka America Pharmaceutical, Inc. | $73.16 |
| Calliditas Therapeutics US Inc. | $65.85 |
| Travere Therapeutics, Inc. | $54.97 |
| Food and Beverage | $1,479 |
|---|---|
| Education | $0.39 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Nov 4, 2025 | Education Filspari · Kidney Disease · in-kind | $0.39 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $194,921 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.